Clinical and intravascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement: does bioresorption matter with small vessel size? Insight from the ABSORB cohort B trial
Roberto Diletti, Vasim Farooq, Chrysafios Girasis, Christos Bourantas, Yoshinobu Onuma, Jung Ho Heo, Bill D Gogas, Robert-Jan van Geuns, Evelyn Regar, Bernard de Bruyne, Dariusz Dudek, Leif Thuesen, Bernard Chevalier, Dougal McClean, Stephan Windecker, Robert J Whitbourn, Pieter Smits, Jacques Koolen, Ian Meredith, Xiaolin Li Show all
Heart | BMJ PUBLISHING GROUP | Published : 2013
BACKGROUND: The long-term results after second generation everolimus eluting bioresorbable vascular scaffold (Absorb BVS) placement in small vessels are unknown. Therefore, we investigated the impact of vessel size on long-term outcomes, after Absorb BVS implantation. METHODS: In ABSORB Cohort B Trial, out of the total study population (101 patients), 45 patients were assigned to undergo 6-month and 2-year angiographic follow-up (Cohort B1) and 56 patients to have angiographic follow-up at 1-year (Cohort B2). The pre-reference vessel diameter (RVD) was <2.5 mm (small-vessel group) in 41 patients (41 lesions) and ≥2.5 mm (large-vessel group) in 60 patients (61 lesions). Outcomes were compared..View full abstract
The present study was funded by Abbott Vascular.